7Baggers
The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.

Mineralys Therapeutics, Inc.
(NASDAQ:MLYS) 

MLYS stock logo

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in...

Founded: 2019
IPO Price: $16 (Feb 10, 2023)
CEO: Jon Congleton  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
Mineralys Therapeutics . Op Cashflow Per Share ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.02-1.74-1.45-1.16-0.87-0.58-0.290
Mineralys Therapeutics . Free Cashflow Per Share ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 -2.02-1.74-1.45-1.16-0.87-0.58-0.290
Mineralys Therapeutics . Cash Per Share ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 01.553.14.656.27.759.310.85
Mineralys Therapeutics . (GAAP) P/E ratio ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 -12.68-10.87-9.06-7.25-5.44-3.62-1.810
Mineralys Therapeutics . P/B ratio ttm
202308 202309 202310 202311 202312 202401 202402 202403 202404 00.330.660.991.331.661.992.32
No extra charts and metrics for this ticker.